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Abstract
Background: Transfemoral approach (TFA) is the most common access route for transcatheter aortic 
valve implantation (TAVI). Percutaneous femoral access (PA) is preferred over the surgical approach 
(SA), however, may be associated with a higher risk of access site complications. Thus, we aimed to 
assess outcomes of computed tomography-guided tailored approach to percutaneous and surgical TFA 
in patients undergoing TAVI. 
Methods: We evaluated data of 158 patients, who underwent TAVI via femoral route between January 
2017 and December 2018. In the PA group, vascular closure was performed with the use of two percutaneous 
suture devices and an additional mechanical seal device. We compared complications rate and outcomes.
Results: Of the 158 patients (92%; mean age 79.6 years, 60.8% female), in 92 (61%) patients PA was 
performed and in 66 (39%) patients SA was used. Median (interquartile range) radiation exposure 
as well as contrast volume dose was higher in the PA group compared to the SA group 614.0 (410.0; 
1104.0) mGy vs. 405 (240.5; 658.0) mGy (p < 0.001) and 150.0 (120.0; 180.7) mL vs. 130.0 (100.0; 
160.0) mL (p = 0.04), respectively. Bleeding complications were similar in the PA group 11 (12.2%) 
compared to 5 (8.62%) in the SA group (p = 0.48). Median length of hospital stay was also similar 
in the PA and the SA group 6.00 (5.00; 8.00) days vs. 6.00 (4.00; 8.00) days, respectively (p = 0.31). 
Conclusions: Computed tomography-guided PA in TAVI may provide comparable procedural out-
comes compared to the SA, despite a higher radiation dose and the use of contrast dye, while being less 
invasive. (Cardiol J)
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Transcatheter aortic valve implantation (TAVI) 
has emerged as a favorable alternative to conven-
tional surgical aortic valve surgery, for high-risk 
patients presenting severe aortic stenosis [1]. 
Over the years, several approaches have been 
introduced such as: transfemoral, transapical, 
subclavian, direct aortic, transcaval or even via 
carotid artery [2, 3]. However, the transfemoral 
approach remains the most favorable access with 
superior outcomes compared to other access 
routes [4, 5]. Initially, access to femoral artery was 
obtained with a surgical cut down in most cases, 
yet, due to its disadvantages such as the need of 
general anesthesia, the duration of the procedure 
and longer recovery time, there was an increasing 
need for the development of a less invasive access 
that could successfully overcome those drawbacks 
and follow the minimalist approach [5]. Moreover, 
a fully percutaneous closure of the femoral artery 
with vascular closure devices (VCD) is associated 
with less pain, faster hemostasis, mobilization, and 
quicker hospital discharge when compared with the 
surgical cut down [6]. Currently, there are several 
VCD systems available for large vessels — Pros-
tar XL (Abbott, USA), Perclose Proglide (Abbott, 
USA), Manta (Teleflex, USA) and Angio-Seal 
(Abbott, USA) [7–12]. In our study, we aimed to 
investigate procedural outcomes and complications 
rate between percutaneous access (PA) with the 
use of two percutaneous suture devices combined 
with one mechanical seal device and surgical ac-
cess (SA).
Methods
Our study was a single center, prospective 
registry in which consecutive patients, who un-
derwent TAVI between January 1, 2017 and De-
cember 31, 2018, were included. All patients were 
scheduled for TAVI by the Heart Team based on 
clinical indications and following multidisciplinary 
evaluation. All procedures were performed by an 
interventional cardiologist and cardiac surgeon, 
acting as a team. The choice between PA and SA 
as well as the left or right femoral artery access 
was left to the operators’ discretion, based on 
a computed tomography (CT) and cardiologist’s and 
surgeon’s consensus. Images from CT were evalu-
ated for optimal access type and puncture site in 
terms of calcifications distribution within femoral 
and iliac arteries as well as their anatomic course. 
Percutaneous access was obtained after cross-over 
angiography performed with a pigtail catheter, to 
determine the optimal puncture site with subse-
quent 6 Fr sheath introduction followed by two 
Proglides insertion and an 8 Fr sheath. Finally, 
a delivery sheath was inserted. In both groups, 
unfractionated heparin was administrated with 
control activated clotting time between 250–300 s. 
TAVI procedure was performed typically under 
analgosedation. For arterial closure, two Proglide 
devices with additional 8 Fr Angio-Seal were used 
in the PA group, after the administration of 50 mg 
protamine sulphate. Cross-over angiography was 
also performed at the end of the procedure to 
exclude bleeding. In the PA direct left ventricle 
wire pacing was the dominant method of pacing 
without access to venous system [13, 14]. Surgical 
access for TAVI required a transverse exposure 
of the common femoral artery. The procedure 
was performed in local anesthesia. It began with 
a skin incision as small as possible to minimize the 
wound size and further complications. The surgeon 
exposed the artery with subsequent puncture of 
the artery and insertion of 6 Fr sheath, followed 
by an exchange for a delivery sheath over the stiff 
wire. For the closure of the femoral artery, a suture 
was used with a subsequent contralateral contrast 
safety injection. Additional contralateral arterial 
and/or venous access sites were also closed with 
6 Fr Angio-Seal devices in both groups.
Baseline clinical and echocardiographic char-
acteristics, together with frailty evaluation by the 
Canadian Study of Health and Aging scale (CSHA) 
and procedural data were assessed [15]. Peri- and 
postprocedural complications, including bleeding, 
were assessed according to The Valve Academic Re-
search Consortium endpoint definitions (VARC-2) 
criteria [16]. Finally, clinical outcomes at 30 days 
were assessed. The study was approved by the 
institutional ethics board.
Statistical analysis
Categorical variables are presented as num-
bers and percentages and were analyzed with 
the Pearson c2 or Fisher exact test. Continuous 
variables are expressed as a mean ± standard 
deviation (SD) for normally distributed variables 
and a median with quartiles for non-normally 
distributed variables. The normality of the data 
was assessed using the Shapiro–Wilk test. The 
groups were compared using the Student t-test for 
normally distributed continuous variables and the 
Mann–Whitney U test for non-normally distrib-
uted continuous variables. P-values < 0.05 were 
considered statistically significant. All statistical 
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analyses were performed using the JMP® Version 
15 (SAS Institute Inc., Cary, NC, USA).
Results
The femoral approach was used in 158 patients 
(mean age 79.6 ± 8.43 years; 59% females). The 
PA group consisted of 92 patients (58.2%; 64.1% 
females). The baseline clinical characteristics was 
similar between both groups (Table 1). Patients in 
the PA group were considered less frail compared 
to the SA group (Fig. 1).
Procedural data are presented in Table 2. The 
radiation dose was significantly higher in the PA 
group compared to the SA group (614.0 [410.0–
1104.0) mGy vs. 405.0 [240.5–658.0] mGy; p < 
< 0.001), while the duration of radiation was only 
slightly higher in the PA group (20.7 [16.0; 26.5] 
min vs. 19.0 [13.9; 22.9] min, p = 0.09). The amount 
of contrast used was also higher in the PA group 
(154.7 ± 50.6 mL vs. 138.9 ± 69.2 mL, p = 0.04).
Table 1. Characteristics of patients in the percutaneous and surgical access groups.
Surgical access  
(n = 66)
Percutaneous  




Age [years], mean ± SD 78.7 ± 10.1 80.3 ± 7.01 79.6 ± 8.43 0.27
Weight [kg], median (IQR) 70.00 (62.00;81.50) 70.00 (62.00;80.00) 70.00 (62.00;80.00) 0.93
BMI [kg/m2], median (IQR) 28.30 (24.78;30.75) 28.00 (25.20;31.45) 28.20 (25.00;31.20) 0.62
Male 29 (43.94%) 33 (35.87%) 62 (39.24%) 0.30
Diabetes melitus 20 (30.77%) 35 (39.33%) 55 (35.71%) 0.34
Atrial fibrilation 23 (35.94%) 38 (42.70%) 61 (39.87%) 0.39
Hypertension 62 (95.38%) 86 (95.56%) 148 (95.48%) 1.00
Dialisys 1 (1.56%) 2 (2.22%) 3 (1.95%) 1.00
GFR [ml/min], mean ± SD 58.97 ± 19.11 56.64 ± 19.69 57.63 ± 19.42 0.46
Creatynine [mmol/L], median (IQR) 90 (76.00;109.00) 91.00 (78.00;119.00) 91.00 (77.00;114.50) 0.36
Hemoglobin [g/dL], mean ± SD 11.92 ± 1.73 11.92 ± 1.80 11.63 ± 1.76 0.75
EuroSCoRE standard 8.83 ± 2.77 8.98 ± 2.50 8.92 ± 2.61 0.74
Logistic EuroSCoRE [%] 15.9 ± 12.7 16.1 ± 14.1 16.0 ± 13.5 0.93
EuroSCoRE 2 [%] 4.12 ± 3.15 4.10 ± 3.32 4.11 ± 3.22 0.97
STS [%] 4.45 ± 2.51 4.56 ± 3.37 4.50 ± 2.97 0.85
DAPT 16 (24.24%) 18 (19.56%) 34 (21.52%) 0.39
Ejection fraction [%], median (IQR) 60.00 (55.00;65.00) 60.00 (50.00;65.00) 60.00 (50.00;65.00) 0.19
AVA [cm2], median (IQR) 0.80 (0.60;0.90) 0.70 (0.60;0.90) 0.80 (0.60;0.90) 0.55
AVMG [mmHg], median (IQR) 45.00 (38.00;55.00) 47.00 (36.75;55.25) 46.00 (37.50;55.00) 0.84
AVPG [mmHg], median (IQR) 70.00 (60.75;94.00) 76.00 (63.00;91.00) 73.00 (62.00;91.00) 0.41
AVA — aortic valve area; AVMG — aortic valve mean gradient; AVPG — aortic valve peak gradient; BMI — body mass index; DAPT — dual 
antiplatelet therapy: EuroSCoRE — European System for Cardiac operative Risk Evaluation; GFR — glomerular filtration rate; IQR — inter-


















































Number of points according to the CSHA scale
Figure 1. Percentage values of patient`s scores accord-
ing to Clinical Frailty Syndrome CSHA Scale (Canadian 
Study of Health and Aging scale [CSHA]) (p < 0.001).
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In the PA group, direct left ventricle wire 
pacing was performed in 66.3% compared to the 
SA group only 39.4% (p = 0.003). Bleeding com-
plications after index procedure occurred in 11 
patients in the PA group and in 5 patients in the SA 
group (12.4% vs. 8.6%, p = 0.48). In both groups, 
most bleeding complications were associated 
with the access site. There was 1 case of cardiac 
tamponade in each group, related to an aortic ring 
rupture. Three bleeding events were associated 
with periprocedural blood loss, 2 (2.2%) in PA and 
1 (1.5%) in the SA group. Eight (8.7%) episodes 
of bleeding in the PA group were related with the 
access site, 3 (3.3%) of them were associated with 
access for control angiography. Respectively, there 
were 3 (4.8%) bleeding episodes in SA group, while 
1 (1.5%) of them was associated with access for 
control angiography. There were 2 cases of life-
threatening bleeding in both groups (2.2% of the 
PA group and 3.0% of the SA group, p = 0.06), 
4 cases of major bleeding in the PA group (4.3%) 
and 2 in the SA group (3.0%), p = 0.06, and 5 cases 
of minor bleeding in the PA group (5.4%) and 1 in 
the SA group (1.5%), p = 0.06. The groups of pa-
tients did not differ in terms of the lowest median 
of blood hemoglobin level 9.9 g/dL (9.2–11.1) vs. 
10.0 g/dL (8.8; 11.4), p = 0.71. The transfusion of 
packed red blood cells occurred more frequently 
in the PA group (15 cases, 16.8%) than in the SA 
group (5 cases, 8.1%), but it was not statistically 
significant (p = 0.12). An ischemic stroke occurred 
in 4 patients in the PA group (4.3%) and 2 cases 
were qualified as major and minor strokes (2.2% 
each). In the SA group, there was no case of stroke; 
however, the difference between the groups was 
not significant (p = 0.45). All of the complications 
are presented in Table 3. There was no statistical 
difference in need for the use of dual antiplatelet 
therapy 19.6% in PA and 24.2% SA, p = 0.39 
or triple antiplatelet therapy 3.0% PA vs. 2.2% 
SA, p = 1.00. After 1 month of follow-up, there 
was only 1 case of minor access site bleeding as 
a result of local hematoma, which did not require 
a blood transfusion. No cases of death or need for 
re-hospitalization were reported.
Discussion 
Transcatheter aortic valve implantation via 
transfemoral approach is an established valuable 
treatment option for high-risk surgical patients; 
however, bleeding related to the smaller sheath 
size and other vascular complications remain 
relevant concerns [9, 12]. Furthermore, those 
complications have been reported to be quite 
frequent and may be associated with poor clinical 
outcomes, such as increased morbidity in the form 
of acute kidney injury and increased mortality 
Table 2. Procedural data.
Total  
(n = 158)





Self-expandable valve 124 (82.7%) 47 (75.8%) 77 (87.5%) 0.03
Ballon-expandable valve 22 (14.7%) 11 (17.7%) 11 (12.5%) 0.03
Direct left ventricular wire pacing 87 (55.06%) 26 (39.39%) 61 (66.30%) 0.003



























VARC-2 bleeding complications 16 (10.88%) 5 (8.62%) 11 (12.36%) 0.48
Life-threatening 4 (25%) 2  (40%) 2 (18.18%)
Major 6 (37.50%) 2 (40%) 4 (36.36%)
Minor 6 (37.50%) 1 (10%) 5 (45.45%)
Lowest hospitalization
Hemoglobin [g/dL], median IQR 10.00 (9.00;11.15) 9.90 (9.20;11.05) 10.00 (8.80;11.40) 0.71
Blood transfusion 20 (13.25%) 5 (8.06%) 15 (16.85%) 0.12
Hospitalization time [day],  
median (IQR)
6.00 (5.00;8.00) 6.00 (5.00;8.00) 6.00 (4.00;8.00) 0.31
IQR — interquartile range; VARC — Valve Academic Research Consortium
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[9, 16]. Our study showed that the most common 
complications in the transfemoral approach for 
TAVI were bleeding events related to vascular ac-
cess. Their incidence was similar in both groups, 
despite PA group being less frail, what impacts 
outcomes crucially [17]. These results were in 
line with similar studies directly comparing full 
percutaneous technique with surgical puncture and 
closure [18]. Moreover, observations herein, sup-
port the idea of teamwork between interventional 
cardiologist and cardiac surgeon and their consen-
sus about the type of vascular access tailored by 
the CT assessment. However, the present results 
are contrary to the findings by Walas et al. [16], 
who compared vascular access site complications 
between the two approaches in a large group of 
patients and reported higher risks of all vascular 
complications in the PA group and highlighting SA 
as a safer option. On the other hand, the patients 
included in the two arms of that study were not 
identical in terms of body mass index (BMI) and 
comorbidities, which may have strongly affected 
the results. In the current study, no statistically 
significant differences were found in BMI, kidney 
function, hypertension, diabetes and preproc-
edural hemoglobin between the study groups. 
Also, regarding the need for dual — and triple — 
antiplatelet therapy no statistical differences were 
found that may have had an impact on bleeding 
complications. As previously mentioned, there 
are three main VCD systems currently available. 
A comparison between Proglide and Prostar re-
vealed a higher incidence of major vascular compli-
cations or in-hospital mortality in the Prostar group 
[10]. It also appears that the recently introduced 
collagen plug-based Manta device in Europe, is 
characterized by higher rates of vascular complica-
tions and non-significantly higher rates of urgent or 
subacute vascular surgery or other endovascular 
surgery [9]. All these findings highlighted that 
Proglide may be comparable to the outcomes of 
the surgical approach. 
Nowadays, we observe a trend towards mini-
malization the complexity of the TAVI procedure. 
Direct left ventricular wire pacing is a handy tool 
because it does not require additional venous ac-
cess [13, 14]. Even though, in the present study, 
direct left ventricle pacing was significantly more 
frequent in PA, a beneficial effect was not observed 
on the reduction of bleeding complications in this 
group. What was different in the current study, to 
achieve hemostasis in the PA group, two Proglides 
with additional Angio-Seal and administration of 
protamine sulphate were used. An appropriate dose 
adjusted to the heparin dose was administered at 
the end of the procedure to reverse unfractionated 
heparin and achieve potential benefits in reducing 
bleeding complications [19]. The present study 
showed a lower incidence of all bleeding com-
plications (12.2% vs. 28.6%) associated with the 
access site in the PA with additional Angio-Seal 
compared to closure with two Proglides solely, 
but still with a higher incidence than in the SA 
group [20–22]. These results may be influenced 
by the study team design, which consisted of an 
interventional cardiologist and a cardiac surgeon 
with extensive vascular experience. Each choice 
between access type, was preceded by a detailed 
analysis of the calcification distribution in CT 
(Fig. 2). The length of the calcified plaques along 
the axis of the vessel played a major role in choos-
ing the most appropriate approach. A long section 
Table 3. Major periprocedural complications. 
Total  
(n = 158)





Valve displacement 1 (0.6%) 0 (0.0%) 1 (1.1%) 0.29
Second valve, bailout 4 (2.5%) 2 (3%) 2 (2.2%) 0.64
AVB requiring PM* 18 (11.8%) 9 (13.6%) 9 (9.8%) 0.75
Cardiogenic shock 5 (3.2%) 1 (1.5%) 4 (4.3%) 0.41
Conversion to surgery 0 (0.0%) 0 (0.0%) 0 (0.0%) NA
Cardiac tamponade 2 (1.3%) 1 (1.5%) 1 (1.1%) 0.85
Acute renal failure 1 (0.6%) 0 (0.0%) 1 (1.1%) 0.54
Myocardial infarction 1 (0.6%) 1 (1.5%) 0 (0.0%) 0.60
Stroke 4 (2.5%) 0 (0.0%) 4 (4.3%) 0.42
Death* 2 (1.3%) 1 (1.5%) 1 (1.1%) 0.85
Data are presented as number and percentage. *During in-hospital stay. AVB — atrioventricular block; NA — not applicable; PM — pacemaker
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of the artery covered by atherosclerotic plaques 
with calcifications is associated with more prob-
lematic hemostasis achievement, when using the 
VCDs (Fig. 2). Patients with a CT scan revealing 
extensive calcifications of the common femoral 
artery, were referred to the SA approach. Bulky or 
circumferential calcification in the femoral artery 
may cause an inability of a proper automated me-
chanical suture deployment which may be followed 
by bleeding. In our opinion, a proper qualification 
of patients with extensive, long calcified athero-
sclerotic plaques for the SA seems to be crucial in 
reducing bleeding complications in TAVI. In the 
present study a trend towards shorter hospital 
stay in the PA group was not noted. Nevertheless, 
the fact that in the PA group blood transfusions 
were more frequent, and could also have had the 
effect of extending hospital stay. Early discharge 
has not only been a subject of numerous studies 
[23–27] but has also been reported to improve the 
outcomes and quality of life after the interventional 
procedures [25]. Aldalati et al. [26] demonstrated 
significant reduction in the hospital stay duration 
in cases with VCD. In their study, early discharge 
Figure 2. Step by step obtaining vascular access in the surgical and percutaneous groups; A. Surgical access — 
femoral artery with long, extensive atherosclerotic plaques; B. Surgical access — femoral artery puncture; C. Surgical 
femoral artery closure; D. Percutaneus access — femoral artery with point atherosclerotic plaques; E. Percutaneous 
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was observed in 71% of patients with transfemoral 
PA approach vs. 22% observed in patients with 
the SA. Furthermore, PA has been reported to 
be associated with shortened hospital stay and 
lower post-procedural complications and major 
adverse cardiac and cerebrovascular events [28]. 
Other studies have reported that the transfemoral 
approach, in general, is an independent factor for 
early discharge [27].
In a study by Giordano el al. [29] compared 
acute and 1-month outcomes of patients undergo-
ing TAVI using as VCD either Proglide or Prostar 
during TAVI. Despite similar device success rates, 
Prostar was associated with a lower risk of vascular 
stenosis, but a higher rate of device malfunction. Un-
adjusted analysis for 1-month outcomes suggested 
higher rates of major adverse events, any bleeding, 
major bleeding, and renal failure in patients receiv-
ing Prostar. However, propensity score-adjusted 
analysis did not confirm any significant differences, 
suggesting that confounding factors mostly drove 
unadjusted differences. They concluded that the use 
of Proglide and Prostar as VCD of choice for TAVI 
appears similarly safe and effective, despite some 
potential benefits associated with Proglide.
The risk of failure or closure of devices and of 
consequent complications can also be estimated us-
ing CT. Currently, available studies have reported 
a higher incidence of failure in cases of circum-
ferential calcification of the vessel wall, which 
involves more than 90° and distance of > 80 mm 
between the skin surface and common femoral 
artery measured at an optimal angle of 45° for 
puncture [30]. These findings in combination with 
a high score in clinical frailty syndrome may help 
determine good candidates for conventional surgi-
cal femoral access during TAVI. 
Limitations of the study
Some important limitations should be noted. 
The present study represents a single-center ex-
perience with a relatively small sample size which 
could be regarded as a limitation of the study. The 
study was not randomized. This is a potential 
limitation, however, it may provide a real-world 
description of a single center experience. How-
ever, the complete analysis of consecutive patients 
without any exclusion criteria and with follow-up 
data for all patients was performed.
Conclusions 
Computed tomography-guided percutaneous 
femoral access in TAVI may provide comparable 
procedural outcomes compared to the SA, despite 
a higher radiation dose and the use of contrast 
dye, while being less invasive. It is necessary to 
emphasize the importance of the role of teamwork 
played between interventional cardiologist and 
cardiac surgeon in final decisions about optimal 
access based on CT assessment. 
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